Publications by authors named "L D Lines"

Aim: To provide an overview of clinical supervision models and frameworks used in nursing and map them to their areas of use in nursing.

Design: A scoping review guided by JBI methodology for scoping reviews.

Methods: A systematic search using CINAHL, Medline, PsycINFO, ERIC, and Emcare databases for English-language papers published at any time and ProQuest and Google Scholar databases for unpublished guidelines was conducted in June 2023 and repeated in June 2024.

View Article and Find Full Text PDF

Purpose: This study aimed to explore nurse perceptions of barriers and facilitators to weaning humidified high flow nasal cannula (HHFNC) in Australian paediatric settings.

Design And Methods: A qualitative descriptive two phased study was conducted across Australia. Purposeful sampling and snowballing technique were used to recruit nurses with the study advertised widely on social media nursing groups.

View Article and Find Full Text PDF

Aim: This study explored Australian nursing, midwifery and social work perspectives on needs within pre-service education to enable interprofessional public health responses to child maltreatment.

Background: Child maltreatment is a global public health concern, but little is known about how well health and welfare professionals are equipped for interprofessional responses to child maltreatment during initial pre-service qualification.

Design: Qualitative, World Café approach with online roundtable discussions.

View Article and Find Full Text PDF

Neoadjuvant intratumoral (IT) therapy could amplify the weak responses to checkpoint blockade therapy observed in breast cancer (BC). In this study, we administered neoadjuvant IT anti-canine PD-1 therapy (IT acPD-1) alone or combined with IT cowpea mosaic virus therapy (IT CPMV/acPD-1) to companion dogs diagnosed with canine mammary cancer (CMC), a spontaneous tumor resembling human BC. CMC patients treated weekly with acPD-1 (n = 3) or CPMV/acPD-1 (n = 3) for four weeks or with CPMV/acPD-1 (n = 3 patients not candidates for surgery) for up to 11 weeks did not experience immune-related adverse events.

View Article and Find Full Text PDF